Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease
Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in a Phase III study of adult patients with a rare, bacteria-driven lung disease.
You may also be interested in...
Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population
Amikacin liposome inhalation suspension seeking accelerated approval to treat nontubercuolous mycobacterial lung disease caused by Mycobacterium avium complex in adults but has only studied patients with refractory disease; agency also wants its advisory committee to opine on confirmatory trial design.
Breathing Life Into Inhaled Antibiotics: US FDA Tries To Move Class Ahead After Two Rejections
Workshop on inhaled antibiotics serves as unusual post mortem after two public rejections at advisory committee level; agency clearly eager not to see development in field end.
Spring Awakening: NDA Submissions To Watch For
If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March.